首页> 外文会议>Hemophilia Symposium >In Vivo-Assay for Warfarin-Resistance by Coexpression of VK0RC1 and Vitamin K-Dependent Coagulation Factors
【24h】

In Vivo-Assay for Warfarin-Resistance by Coexpression of VK0RC1 and Vitamin K-Dependent Coagulation Factors

机译:在VK0RC1和维生素K依赖性凝血因子的共同抑制方面的体内测定

获取原文

摘要

Vitamin K serves as a cofactor for the post-translational modification by gamma-car-boxylation of several proteins with Gla-domains. Vitamin K-dependent proteins include the coagulation factors II, VII, IX, and X and proteins S, C and Z, illustrating the therapeutic importance of vitamin K metabolism. Inhibitors of the Coumarin-type like Warfarin or Marcumar reduce coagulation activity by interfering with the vitamin K 2,3-epoxide reductase enzyme complex (VKOR). They are the most used oral anticoagulants for antithrombotic prophylaxis.Previously we have shown that mutations in the VK0RC1 lead to combined deficiency of vitamin-K-dependent clotting factors type 2 (VKCFD2; OMIM: 607473) or Warfarin resistance.
机译:维生素K用作由Gamma-Car-Boxy化与GLA结构蛋白的γ-型丙烷化的翻译后修饰的辅助因子。维生素K依赖性蛋白质包括凝血因子II,VII,IX和X和蛋白S,C和Z,说明维生素K代谢的治疗重要性。香豆素型的抑制剂如华法林或Marcumar等通过干扰维生素K 2,3-环氧化物还原酶酶(VKOR)来减少凝血活性。它们是抗血栓性预防最常用的抗凝血剂。因此,我们已经表明,VK0RC1中的突变导致维生素-K依赖性凝血因子2型(VKCFD2; OMIM:607473)或华法素抗性的组合缺乏。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号